The Cost Concentration Crisis: Few Scripts, Most of the Spend
Brokers know the story: a handful of prescriptions can dominate a group’s costs, and in small groups, one member can swing the entire renewal. Today, specialty drugs represent a disproportionate share of pharmacy spending despite a minority of total scripts. This post lays out the drivers behind premium pressure and volatility in the small‑group market—and invites you to a private, broker‑only strategy review.
Request a Small‑Group Risk Analysis with your Optimyl Sales Advisor Today
Why Small Employers Are Disproportionately Exposed
- Small pool, big swings: One specialty claimant can dominate experience and drive double‑digit renewals—even when everyone else is healthy.
- Higher member cost burden: Small firms tend to have higher deductibles and higher family premium shares than large firms—compounding affordability pressure.
- Level‑funded exposure: More small employers are in arrangements that tie performance to renewal—making pharmacy volatility immediately visible in pricing.
When you brief a CFO, emphasize that the problem isn’t “drugs in general”—it’s the concentration of spend in a few high‑cost therapies and channels.
Catastrophic Claims Are Rising—and More Concentrated
Million‑dollar claims are up significantly year‑over‑year and over the last several years, with cancer and specialty injectables dominating top cost categories. For small groups, the takeaway is simple: the frequency and severity of outlier claims keep trending upward—and stop‑loss reimbursements are clustered in a narrow set of conditions.
What Brokers Can Do Now (Without Guesswork)
- Lead with concentration, not averages: Show how a few therapies drive most spend; clarify list vs. net when citing numbers.
- Quantify vulnerability: Model a single claimant scenario against renewal impacts for a 25‑, 75‑, and 150‑life census.
- Bring visuals: Use one chart on specialty share and one on million‑dollar claims to frame the CFO conversation.
Need a ready‑to‑use script? Let Optimyl help frame the conversation along with you
A Broker‑First Path
Optimyl partners exclusively through brokers to confront pharmacy inflation in small groups using modern, data‑driven approaches. We take a unique approach to addressing the cost of specialty meds while ensuring members receive the care they deserve.
Learn more about our philosophy on our About Us page—then schedule a private briefing with our sales team to see how we protect member access while reducing volatility.